U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Cellular & Gene Therapy Products
  4. RYONCIL
  1. Cellular & Gene Therapy Products

STN: 125706 
Proper Name: remestemcel-L-rknd
Tradename: RYONCIL  
Manufacturer: Mesoblast, Inc. 
Indication:

  • Indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.

Product Information

Supporting Documents

Back to Top